Patents by Inventor Richard B. Silverman

Richard B. Silverman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase
    Patent number: 8829187
    Abstract: Diastereomeric pyrrolidine compounds and methods of preparation, as can be used en route to the preparation of a range of nitric oxide synthase inhibitors.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: September 9, 2014
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Fengtian Xue
  • Benzamide Compounds and Related Methods of Use
    Publication number: 20140234939
    Abstract: Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.
    Type: Application
    Filed: December 23, 2013
    Publication date: August 21, 2014
    Applicant: Northwestern University
    Inventors: Richard B. Silverman, Hua Wang, Mohammad Khanfar
  • Chiral Synthesis of Pyrrolidine Core Compounds en route to Neuronal Nitric Oxide Synthase Inhibitors
    Publication number: 20140228578
    Abstract: A chiral synthesis of pyrrolidine compounds en route to selective neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.
    Type: Application
    Filed: April 14, 2014
    Publication date: August 14, 2014
    Applicant: Northwestern University
    Inventors: Richard B. Silverman, Fengtian Xue
  • Specific nNOS Inhibitors for the Therapy and Prevention of Human Melanoma
    Publication number: 20140147920
    Abstract: Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.
    Type: Application
    Filed: February 3, 2014
    Publication date: May 29, 2014
    Applicants: The Regents of the University of California, Northwestern University
    Inventors: Frank L. Meyskens, JR., Richard B. Silverman, Sun Yang, Haitao Ji, Fengtian Xue, Thomas L. Poulos
  • Thiophene-2-carboximidamide based selective neuronal nitric oxide inhibitors
    Patent number: 8735606
    Abstract: Selective neuronal nitric oxide synthase (nNOS) inhibitor compounds designed with one or more thiophene-2-carboximidamide substituents for improved bioavailability.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: May 27, 2014
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, He Huang, Qing Jing
  • Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis
    Patent number: 8722939
    Abstract: The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 13, 2014
    Assignees: Northwestern University, Cambria Pharmaceuticals, Inc.
    Inventors: Donald R. Kirsch, Radhia Benmohamed, Anthony C. Arvanites, Richard I. Morimoto, Wei Zhang, Richard B. Silverman
  • Inhibitors of the mevalonate pathway of
    Patent number: 8710032
    Abstract: Compounds and related methods as can be used for selective mevalonate pathway inhibitors.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: April 29, 2014
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Takashi Kudoh
  • Chiral synthesis of pyrrolidine core compounds en route to neuronal nitric oxide synthase inhibitors
    Patent number: 8697879
    Abstract: A chiral synthesis of pyrrolidine compounds en route to selective neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: April 15, 2014
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Fengtian Xue
  • Inhibition of ornithine aminotransferase for the treatment of proliferative disorders
    Patent number: 8686041
    Abstract: The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: April 1, 2014
    Assignees: Hadasit Medical Research Services & Development, Ltd., Northwestern University
    Inventors: Yaron Ilan, Ehud Zigmond, Richard B. Silverman, Hejun Lu
  • Thiophene-2-carboximidamide Based Selective Neuronal Nitric Oxide Inhibitors
    Publication number: 20140066635
    Abstract: Selective neuronal nitric oxide synthase (nNOS) inhibitor compounds designed with one or more thiophene-2-carboximidamide substituents for improved bioavailability.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 6, 2014
    Applicant: Northwestern University
    Inventors: Richard B. Silverman, He Huang, Qing Jing
  • Inhibitors of nitric oxide synthase for treatment of melanoma
    Patent number: 8642282
    Abstract: Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: February 4, 2014
    Assignees: Northwestern University, The Regents of the University of California
    Inventors: Frank L. Meyskens, Jr., Richard B. Silverman, Sun Yang, Haitao Ji, Fengtian Xue, Thomas L. Poulos
  • Selective neuronal nitric oxide synthase inhibitors with azole substituents
    Patent number: 8618143
    Abstract: Non-peptide, azole-substituted nitric oxide snythase inhibitor compounds, compositions and related methods, as can be used to enhance bioavailability and inhibit production of nitric oxide.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: December 31, 2013
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, James M. Kraus
  • Selective neuronal nitric oxide synthase inhibitors
    Patent number: 8557552
    Abstract: Compounds and related methods for selective inhibition of neuronal nitric oxide synthase over inducible and endothelial isoforms, such compounds as can provide reduced cationic character and enhanced bioavailability.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: October 15, 2013
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Haitao Ji, He Huang
  • Prodrugs of Fluorinated Mevalonates to Inhibit the Mevalonate Pathway of Streptococcus pneumoniae
    Publication number: 20130245284
    Abstract: Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition.
    Type: Application
    Filed: February 28, 2013
    Publication date: September 19, 2013
    Inventors: Richard B. Silverman, Mizuki Watanabe, Soosung Kang
  • Cyclic peptide antitumor agents
    Patent number: 8492345
    Abstract: Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: July 23, 2013
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Shouxin Liu, Wenxin Gu, Thomas E. Adrian, Gerald A. Soff
  • Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase
    Patent number: 8389731
    Abstract: Diastereomeric pyrrolidine compounds and methods of preparation, as can be used en route to the preparation of a range of nitric oxide synthase inhibitors.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: March 5, 2013
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Fengtian Xue
  • METHODS OF USING (1S,3S)-3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACID
    Publication number: 20130041028
    Abstract: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).
    Type: Application
    Filed: February 25, 2011
    Publication date: February 14, 2013
    Applicants: NORTHWESTERN UNIVERSITY, CATALYST PHARMACEUTICAL PARTNERS, INC., BROOKHAVEN SCIENCE ASSOCIATES
    Inventors: Richard B. Silverman, Stephen L. Dewey, Steven Miller
  • Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability
    Patent number: 8299100
    Abstract: Compounds and related compositions and methods as can be used to inhibit neuronal nitric oxide synthase and can be employed in the treatment of various neurodegenerative diseases, such compounds of a formula
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: October 30, 2012
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Fengtian Xue
  • Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis
    Publication number: 20120264765
    Abstract: The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.
    Type: Application
    Filed: October 29, 2010
    Publication date: October 18, 2012
    Applicants: Cambria Pharmaceuticals, Inc., Northwestern University
    Inventors: Donald R. Kirsch, Radhia Benmohamed, Anthony C. Arvanties, Richard I. Morimoto, Wei Zhang, Richard B. Silverman
  • Selective Neuronal Nitric Oxide Synthase Inhibitors
    Publication number: 20120258513
    Abstract: Compounds and related methods for selective inhibition of neuronal nitric oxide synthase over inducible and endothelial isoforms, such compounds as can provide reduced cationic character and enhanced bioavailability.
    Type: Application
    Filed: April 6, 2012
    Publication date: October 11, 2012
    Inventors: Richard B. Silverman, Haitao Ji, He Huang